LSA
ALLO icon

Leonteq Securities AG’s Allogene Therapeutics ALLO Stock Holding History

Leonteq Securities AG’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$730 Hold
351
– – ﹤0.01% 1195
2026
Q1 		$856 Hold
351
– – ﹤0.01% 1201
2025
Q4 		$481 Hold
351
– – ﹤0.01% 1376
2025
Q3 		$435 Hold
351
– – ﹤0.01% 1277
2025
Q2 		$397 Hold
351
– – ﹤0.01% 1226
2025
Q1 		$512 Hold
351
– – ﹤0.01% 1182
2024
Q4 		$748 Hold
351
– – ﹤0.01% 1196
2024
Q3 		$983 Hold
351
– – ﹤0.01% 1123
2024
Q2 		$818 Buy
+351
New +$1.03K ﹤0.01% 1138
2022
Q4 		– Sell
-7,500
Closed -$81K – 1291
2022
Q3 		$81K Buy
7,500
+500
+7% +$6.79K ﹤0.01% 689
2022
Q2 		$79.8K Buy
7,000
+2,500
+56% +$22.2K ﹤0.01% 726
2022
Q1 		$41K Buy
+4,500
New +$46.9K ﹤0.01% 899
2021
Q3 		– Sell
-122
Closed -$3.18K – 1129
2021
Q2 		$3.18K Sell
122
-1
-0.8% -$29 ﹤0.01% 1032
2021
Q1 		$4.34K Sell
123
-11,269
-99% -$380K ﹤0.01% 949
2020
Q4 		$288K Buy
+11,392
New +$371K 0.02% 510

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Leonteq Securities AG's ALLO Position: Q2 2026 in Review

Leonteq Securities AG held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 351 shares worth $730. The position accounts for ﹤0.01% of the portfolio, ranked #1195.

Leonteq Securities AG first reported a position in ALLO in Q4 2020 and has held it in 15 quarters since. The position peaked at $288K in Q4 2020. 207 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Leonteq Securities AG held 351 shares of Allogene Therapeutics worth $730 as of Q2 2026.
  • Leonteq Securities AG left its Allogene Therapeutics share count unchanged in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of Leonteq Securities AG's portfolio in Q2 2026, its #1195 holding.
  • Leonteq Securities AG first reported a position in Allogene Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • Leonteq Securities AG's Allogene Therapeutics position peaked at $288K in Q4 2020.
  • 207 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.